Pfenex (PFNX) Posts Robust Q3 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. HUM
8. NVDA
9. CSCO
10. KTOS

Go back to Pfenex (PFNX) Posts Robust Q3 Results

Pfenex Reports Third Quarter 2016 Results and Provides Business Update

November 9, 2016 4:05 PM EST

SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the third quarter ended September 30, 2016 and provided a business update.

"In the third quarter, Pfenex has continued to make steady progress, advancing our broad pipeline of biosimilar therapeutics and government funded anthrax vaccine candidates," stated Bertrand C. Liang, Chief Executive Officer of Pfenex. ... More